Endocare Board OKs ‘Poison Pill’ Strategy
- Share via
Irvine-based Endocare Inc. said Monday its board has approved a “poison pill” designed to thwart any hostile takeover bid.
Under the plan, shareholders will receive rights to purchase a larger stake in the company, which manufactures surgical devices, if a person or group acquires more than 15% of Endocare’s stock.
The rights will be issued to shareholders on April 15 as a dividend.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
